Skip to content

Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome

Source: ClinicalTrials.gov – Retinitis Pigmentosa – Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome


Condition:   Alström Syndrome
Intervention:   Drug: PBI-4050
Sponsor:   ProMetic BioSciences Inc.
Not yet recruiting – verified June 2017


Source: ClinicalTrials.gov – Retinitis Pigmentosa – Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest
Published inReports & Studies

Be First to Comment

Leave a Reply